Modality
Vaccine
MOA
FGFRi
Target
AuroraA
Pathway
PI3K/AKT
HSAS
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
Oct 2021
→ Aug 2030
Phase 1Current
NCT08614547
1,607 pts·HS
2021-10→2026-01·Not yet recruiting
NCT08684419
1,512 pts·HS
2023-03→2030-08·Active
3,119 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-01-282mo agoPh2 Data· HS
2026-04-022d awayFast Track· AS
2030-08-084.4y awayPh2 Data· HS
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Not yet…
P1/2
Active
Catalysts
Ph2 Data
2026-01-28 · 2mo ago
HS
Fast Track
2026-04-02 · 2d away
AS
Ph2 Data
2030-08-08 · 4.4y away
HS
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08614547 | Phase 1/2 | HS | Not yet recr... | 1607 | BodyWt |
| NCT08684419 | Phase 1/2 | HS | Active | 1512 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA |